This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score testfor patients diagnosed with estrogen receptor–positive, human epidermal growth factor 2–negative, and node-negative invasive breast cancer.

If you have a Hayes login, click here to view the full report on the Knowledge Center.